Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | AOC1 | P19801 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 3/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23609143 | 0.92 | SMN1; SMN2 (0.41) | PDE5AALDH1A1HTTSMN1; SMN2ITK | |
| SCHEMBL23609145 | 0.79 | FLT1 (0.43) | GSK3BPDE5ADYRK1AALDH1A1HTT | |
| SCHEMBL23609770 | 0.75 | CSNK2A2 (0.38) | GSK3BPDE5AALDH1A1 | |
| SCHEMBL23579205 | 0.74 | QPCT (0.35) | S1PR1GSK3B | |
| SCHEMBL23608999 | 0.73 | CYP19A1 (0.43) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23609003 | 0.73 | SMN1; SMN2 (0.44) | GSK3BALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23609264 | 0.71 | SMN1; SMN2 (0.42) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23608952 | 0.69 | PDE5A (0.36) | S1PR1KDM4CAOC1AOC3PDE5A | |
| SCHEMBL30406454 | 0.69 | CYP1A2 (0.45) | PDE5AALDH1A1 | |
| SCHEMBL23609230 | 0.68 | SMN1; SMN2 (0.46) | ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4081199-A2 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133689-A2 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX5 | S1PR1 1802/4885GSK3B 2662/4885KDM4C 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.